LUXEMBOURG—Following its decision to enforce stricter health rules and guidelines for its producers and performers, Manwin has purchased the Gen Probe Aptima machine for Cutting Edge Testing.
This piece of equipment performs the Aptima RNA Qualitive Assay, the FDA approved test that Manwin requires as part of the new health standards and procedures from producers, performers and agents.
While researching its new guidelines, Manwin collaborated with various North American health experts and organizations. During this time period, Dr. Peter Miao became a great source of information and support. The renowned infectious disease expert, who was part of the original team of physicians that encountered HIV infections in 1981, oversees the Cutting Edge Testing center.
“Aptima testing by Gen Probe has been available for many years, and is approved by the FDA for the diagnosis of acute HIV infection," Dr. Miao said. "At Cutting Edge Testing, we are now transitioning to the Aptima test for screening of HIV [infections] very shortly."
Manwin is pleased to support Dr. Miao and Cutting Edge Testing.
“This demonstrates Manwin’s concern for the health and safety of all the performers and the industry as a whole,” says Dr. Miao. “By their generous gift, we now can move ahead and perform the Aptima test in the very near future.”
Manwin hopes that the donation will help Dr. Miao and his team continue their work in providing optimal health services to adult entertainment professionals, as well as the public at large.
All models were at least 18 years old at the time of their performance. 18 U.S.C. 2257 Record-Keeping Requirements Compliance Statement.
